These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8449840)

  • 1. Pharmacoeconomics of antimicrobial prophylaxis.
    Davey PG; Parker SE; Malek MM
    J Antimicrob Chemother; 1993 Feb; 31 Suppl B():107-18. PubMed ID: 8449840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacoeconomics of infection in the intensive care unit].
    Grau S; Alvarez-Lerma F
    Rev Esp Quimioter; 2008; 21 Spec No 1():26-34. PubMed ID: 18752077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics of antibacterial treatment.
    Davey PG; Malek MM; Parker SE
    Pharmacoeconomics; 1992 Jun; 1(6):409-37. PubMed ID: 10147022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibiotic pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for antibiotic use in ICU patients: a one-year prospective surveillance.
    Bergmans DC; Bonten MJ; Gaillard CA; van Tiel FH; van der Geest S; de Leeuw PW; Stobberingh EE
    J Antimicrob Chemother; 1997 Apr; 39(4):527-35. PubMed ID: 9145828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Main variables in the economic cost of treating an infection].
    Grau S
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():41-45. PubMed ID: 28129821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of broad-spectrum antibiotic prophylaxis on intracranial pressure monitor infections and subsequent infectious complications in head-injured patients.
    May AK; Fleming SB; Carpenter RO; Diaz JJ; Guillamondegui OD; Deppen SA; Miller RS; Talbot TR; Morris JA
    Surg Infect (Larchmt); 2006 Oct; 7(5):409-17. PubMed ID: 17083307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of antibiotic treatment of healthcare-associated infections at a tertiary care hospital ICU in Goa, India.
    Misal DD; Maulingkar SV; Bhonsle S
    Trop Doct; 2017 Jul; 47(3):197-201. PubMed ID: 27307475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial stewardship: bridging the gap between quality care and cost.
    Goff DA
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
    van Dalen EC; Mank A; Leclercq E; Mulder RL; Davies M; Kersten MJ; van de Wetering MD
    Cochrane Database Syst Rev; 2012 Sep; (9):CD006247. PubMed ID: 22972091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The choice of antimicrobial therapy by application of pharmacoeconomic principles in view of the most frequently isolated pathogens at the Clinic for Infectious Diseases of the Clinical Center of Vojvodina].
    Stefan-Mikić S; Sević S; Jovanović N; Cvjetković D; Aleksić-Dordević M
    Med Pregl; 2010; 63 Suppl 1():52-9. PubMed ID: 21438205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis.
    Courville XF; Tomek IM; Kirkland KB; Birhle M; Kantor SR; Finlayson SR
    Infect Control Hosp Epidemiol; 2012 Feb; 33(2):152-9. PubMed ID: 22227984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current communicable disease control--part 2. What does it cost and who is to pay?].
    Källenius G; Andersson D
    Lakartidningen; 2000 Oct; 97(42):4732-6. PubMed ID: 11079324
    [No Abstract]   [Full Text] [Related]  

  • 16. [Scientific evidence and antimicrobial therapy: A perfect couple?].
    Jovell AJ
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():9-14. PubMed ID: 10605184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial prophylaxis in 'clean' surgery: hernia repair.
    Ranaboldo CJ; Karran SE; Bailey IS; Karran SJ
    J Antimicrob Chemother; 1993 Feb; 31 Suppl B():35-41. PubMed ID: 8449844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary audit of practice--antibacterial prophylaxis in general surgery in an Indian hospital setting.
    Srishyla MV; Rani MA; Damodar S; Venkataraman BV; Jairam N
    Indian J Physiol Pharmacol; 1994 Jul; 38(3):207-10. PubMed ID: 7814084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis at the margins. Proceedings of a meeting. Bishopstrowe, 9-10 May 1992.
    J Antimicrob Chemother; 1993 Feb; 31 Suppl B():1-128. PubMed ID: 8449837
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement in prescribing habits and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis.
    Hermsen ED; Smith Shull S; Puumala SE; Rupp ME
    Infect Control Hosp Epidemiol; 2008 May; 29(5):457-61. PubMed ID: 18419372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.